Cancer Immunology, Immunotherapy

, Volume 58, Issue 10, pp 1647–1655 | Cite as

Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro

  • Wujiang Liu
  • Michael A. O’Donnell
  • Xiaohong Chen
  • Ruifa Han
  • Yi Luo
Original Article

Abstract

Purpose

The proper induction of cellular immunity is required for effective bacillus Calmette-Guérin (BCG) immunotherapy of bladder cancer. It has been known that BCG stimulation of human peripheral blood mononuclear cells (PBMC) leads to the generation of effector cells cytotoxic to bladder cancer cells in vitro. To improve BCG therapy, we previously developed human interferon (IFN)-α 2B secreting recombinant (r) BCG (rBCG-IFN-α). We demonstrated that rBCG-IFN-α augmented T helper type 1 (Th1) cytokine IFN-γ production by PBMC. In this study, we further investigated whether rBCG-IFN-α could also enhance PBMC cytotoxicity toward bladder cancer cells.

Materials and methods

PBMC were prepared from healthy individuals, left alone or stimulated with rBCG-IFN-α or control MV261 BCG, and used as effector cells in 51Cr-release assays. Human bladder cancer cell lines T24, J82, 5637, TCCSUP, and UMUC-3 were used as target cells. To determine the role of secreted rIFN-α as well as endogenously expressed IFN-γ and IL-2 in inducing the cytotoxicity, PBMC were stimulated with rBCG-IFN-α in the presence of neutralizing antibodies to IFN-α, IFN-γ or IL-2. To determine the role of natural killer (NK) and CD8+ T cells in inducing the cytotoxicity, both cell types were isolated after BCG stimulation of PBMC and used as effector cells in 51Cr-release assays.

Results

Non-stimulated PBMC showed basal levels of cytotoxicity against all target cell lines tested. MV261 BCG increased the PBMC cytotoxicity by 1.8- to 4.2-fold. rBCG-IFN-α further increased the PBMC cytotoxicity by up to 2-fold. Elevated production of IFN-γ and IL-2 by PBMC was observed after rBCG-IFN-α stimulation. Blockage of IFN-α, IFN-γ or IL-2 by neutralizing antibodies during rBCG-IFN-α stimulation reduced or abolished the induction of PBMC cytotoxicity. Both NK and CD8+ T cells were found to be responsible for the enhanced PBMC cytotoxicity induced by rBCG-IFN-α with the former cell type being more predominant.

Conclusions

rBCG-IFN-α is an improved BCG agent that induces enhanced PBMC cytotoxicity against bladder cancer cells in vitro. This rBCG strain may serve as an alternative to BCG for the treatment of superficial bladder cancer.

Keywords

BCG IFN-α Bladder cancer Cytotoxicity 

References

  1. 1.
    Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM (1980) Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 124:38–40PubMedGoogle Scholar
  2. 2.
    O’Donnell MA, DeWolf DC (1995) Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 4:189–202PubMedGoogle Scholar
  3. 3.
    Alexandroff AB, Jackson AM, O’Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689–1694PubMedCrossRefGoogle Scholar
  4. 4.
    Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD (1990) Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144:53–58PubMedGoogle Scholar
  5. 5.
    Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636–1642PubMedGoogle Scholar
  6. 6.
    Peuchmaur M, Benoit G, Vieillefond A, Chevalier A, Lemaigre G, Martin ED, Jardin A (1989) Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette-Guérin. Urol Res 17:299–303PubMedCrossRefGoogle Scholar
  7. 7.
    Saint F, Patard JJ, Groux Muscatelli B, Lefrere Belda MA, Diez Gil, de Medina S, Abbou CC, Chopin DK (2001) Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. BJU Int 88:602–610PubMedCrossRefGoogle Scholar
  8. 8.
    De Boer EC, De Jong WH, Van Der Meijden AP, Steerenberg PA, Witjes JA, Vegt PD, Debruyne FM, Ruitenberg EJ (1991) Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 33:411–416PubMedCrossRefGoogle Scholar
  9. 9.
    De Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, Debruyne FM, Ruitenberg EJ (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 19:45–50PubMedCrossRefGoogle Scholar
  10. 10.
    Bohle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD (1990) Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 144:59–64PubMedGoogle Scholar
  11. 11.
    de Reijke TM, de Boer EC, Kurth KH, Schamhart DH (1996) Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 155:477–482PubMedCrossRefGoogle Scholar
  12. 12.
    Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE (2000) Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol 164:2129–2133PubMedCrossRefGoogle Scholar
  13. 13.
    Poppas DP, Pavlovich CP, Folkman J, Voest EE, Chen X, Luster AD, O’Donnell MA (1998) Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52:268–275PubMedCrossRefGoogle Scholar
  14. 14.
    Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O’Donnell MA, Ratliff TL (2003) Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol 131:206–216PubMedCrossRefGoogle Scholar
  15. 15.
    Luo Y, Chen X, O’Donnell MA (2007) Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 147:370–378PubMedGoogle Scholar
  16. 16.
    Böhle A, Thanhäuser A, Ulmer AJ, Ernst M, Flad HD, Jocham D (1993) Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150:1932–1937PubMedGoogle Scholar
  17. 17.
    Thanhäuser A, Böhle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad HD, Ulmer AJ (1995) The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40:103–108PubMedCrossRefGoogle Scholar
  18. 18.
    Thanhäuser A, Böhle A, Flad HD, Ernst M, Mattern T, Ulmer AJ (1993) Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37:105–111PubMedCrossRefGoogle Scholar
  19. 19.
    Brandau S, Böhle A, Thanhäuser A, Ernst M, Mattern T, Ulmer AJ, Flad HD (2000) In vitro generation of bacillus Calmette-Guérin-activated killer cells. Clin Infect Dis 31(Suppl 3):S94–S100PubMedCrossRefGoogle Scholar
  20. 20.
    Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A (2000) Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette-Guérin-activated killer cells. Clin Cancer Res 6:3729–3738PubMedGoogle Scholar
  21. 21.
    Platts KE, Lawry J, Hancock BW, Rees RC (1993) Phenotypic and cell cycle analysis of human peripheral blood mononuclear cells activated with interleukin-2 and/or OKT3. Exp Cell Res 208:154–160PubMedCrossRefGoogle Scholar
  22. 22.
    Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK (1998) Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 26:155–159PubMedCrossRefGoogle Scholar
  23. 23.
    Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19:573–580PubMedGoogle Scholar
  24. 24.
    Dejager R, Guinan P, Lamm D (1991) Long-term complete remission in bladder carcinoma in situ with intravesical tice bacillus Calmette-Guérin. Urology 38:507–513CrossRefGoogle Scholar
  25. 25.
    Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM (1992) Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147:596–600PubMedGoogle Scholar
  26. 26.
    Bercovich E, Deriu M, Manferrari F, Irianni G (1995) BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 67:257–260PubMedGoogle Scholar
  27. 27.
    Stricker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, Nash P, Ehsman S, Rumma J, Mammen G, Penny R (1996) Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urol 48:957–961PubMedCrossRefGoogle Scholar
  28. 28.
    Luo Y, Chen X, Downs TM, DeWolf WC, O’Donnell MA (1999) IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 162:2399–2405PubMedGoogle Scholar
  29. 29.
    Joudi FN, Smith BJ, O’Donnell MA, National BCG-interferon phase 2 investigator group (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24:344–348PubMedGoogle Scholar
  30. 30.
    Luo Y, Chen X, O’Donnell MA (2003) Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 21:17–26PubMedCrossRefGoogle Scholar
  31. 31.
    Chen X, O’Donnell MA, Luo Y (2007) Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells. Clin Exp Immunol 149:178–185PubMedGoogle Scholar
  32. 32.
    Zhang Y, Khoo HE, Esuvaranathan K (1999) Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. J Urol 161:977–983PubMedCrossRefGoogle Scholar
  33. 33.
    Pryor K, Stricker P, Russell P, Golovsky D, Penny R (1995) Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 41:309–316PubMedCrossRefGoogle Scholar
  34. 34.
    Luo Y, Chen X, Han R, O’Donnell MA (2001) Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123:264–270PubMedCrossRefGoogle Scholar
  35. 35.
    O’Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC (1994) Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 62:2508–2514PubMedGoogle Scholar
  36. 36.
    Brandau S, Böhle A (2001) Activation of natural killer cells by bacillus Calmette-Guérin. Eur Urol 39:518–524PubMedCrossRefGoogle Scholar
  37. 37.
    Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Böhle A (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92:697–702PubMedCrossRefGoogle Scholar
  38. 38.
    Suttmann H, Jacobsen M, Reiss K, Jocham D, Böhle A, Brandau S (2004) Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 172:1490–1495PubMedCrossRefGoogle Scholar
  39. 39.
    Naoe M, Ogawa Y, Takeshita K, Morita J, Iwamoto S, Miyazaki A, Yoshida H (2007) Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Int J Urol 14:532–538PubMedCrossRefGoogle Scholar
  40. 40.
    Biron CA (2001) Interferons alpha and beta as immune regulators—a new look. Immunity 14:661–664PubMedCrossRefGoogle Scholar
  41. 41.
    Atkinson S, Valadas E, Smith SM, Lukey PT, Dockrell HM (2000) Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. Tuber Lung Dis 80:197–207PubMedCrossRefGoogle Scholar
  42. 42.
    Matsumoto H, Suzuki K, Tsuyuguchi K, Tanaka E, Amitani R, Maeda A, Yamamoto K, Sasada M, Kuze F (1997) Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells. Infect Immun 65:4405–4410PubMedGoogle Scholar
  43. 43.
    Esin S, Batoni G, Pardini M, Favilli F, Bottai D, Maisetta G, Florio W, Vanacore R, Wigzell H, Campa M (2004) Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guerin. Immunology 112:143–152PubMedCrossRefGoogle Scholar
  44. 44.
    Seder RA, Gazzinelli R, Sher A, Paul WE (1993) Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon-γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 90:10188–10192PubMedCrossRefGoogle Scholar
  45. 45.
    Mizel SB (1989) The interleukins. FASEB J 3:2379–2388PubMedGoogle Scholar
  46. 46.
    Alvarez-Mon M, Moltó LM, Manzano L, Olivier C, Carballido JA (1992) Immunomodulatory effect of interferon-alpha 2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anticancer Drugs 3(Suppl 1):5–8PubMedCrossRefGoogle Scholar
  47. 47.
    Moltó L, Alvarez-Mon M, Carballido J, Manzano L, Guillen C, Prieto A, Olivier C, Rodriguez-Zapata M (1994) Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer 70:1247–1251PubMedGoogle Scholar
  48. 48.
    Mitropoulos DN (2005) Novel insights into the mechanism of action of intravesical immunomodulators. In Vivo 19:611–621PubMedGoogle Scholar
  49. 49.
    Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726–2734PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Wujiang Liu
    • 1
  • Michael A. O’Donnell
    • 1
  • Xiaohong Chen
    • 1
  • Ruifa Han
    • 2
  • Yi Luo
    • 1
  1. 1.Department of UrologyUniversity of IowaIowaUSA
  2. 2.Tainjin Institute of UrologyTainjinChina

Personalised recommendations